Ciprofloxacin is a second-generation fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, providing broad-spectrum coverage across a wide range of Gram-negative and some Gram-positive pathogens, and remains a first-line agent for UTIs, respiratory infections and gastrointestinal infections. Simson Pharma's Ciprofloxacin reference standard and extensive impurity panel support the high-volume compendial QC this globally essential antibiotic demands.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Ciprofloxacin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.